One meta-analysis found that a high beclin-1 immunolabeling level indicateda more favorable prognosis in gastric cancer and lymphoma, whereas it had noprognostic value in colorectal, breast, and lung cancers.17 Two studies investigating beclin-1 immunolabeling as a predictive markerfound similar results to the current study. This evidence concerns the gene BECN1 and gastric cancer.